The Delhi High Court reiterated that a properly drafted pharmaceutical composition claim cannot be dismissed as a “method of treatment” under Section 3(i), and has sent Medilabo’s neurodegenerative drug application back for a full, merits-based examination.
Read more about Section 3(i) Rejection Set Aside: Court Clarifies Scope of Pharmaceutical Patent Claims